Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
- PMID: 35908559
- DOI: 10.1016/S1470-2045(22)00449-1
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
Conflict of interest statement
AE reports funding from the Canadian Institutes of Health Research, the Royal College of Surgeons and Physicians of Canada, and the Henry R Shibata Research Fellowship. HY has consulted for Daiichi, Janssen, AstraZeneca, Black Diamond, Blueprint, and Cullinan; and reports research funding from Daiichi, Janssen, AstraZeneca, Black Diamond, Blueprint, Novartis, Pfizer, Cullinan, and ERASCA.
Comment on
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
